China Pharma Holdings Inc.
| AMEX: CPHI | Healthcare / Drug Manufacturers / China |
| 0.1390 | +0.0035 | +2.58% | Vol 514.53K | 1Y Perf -90.52% |
| Sep 22nd, 2023 15:59 DELAYED |
| BID | 0.1321 | ASK | 0.1390 | ||
| Open | 0.1400 | Previous Close | 0.1355 | ||
| Pre-Market | - | After-Market | 0.14 | ||
| - - | 0.00 -0.14% |
| Target Price | - | Analyst Rating | — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ☆ 31.62 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ☆ 14.35 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.22 | Earnings Rating | Buy | |
| Market Cap | 1.59M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.25 | |
| Beta | 0.54 |
Today's Price Range 0.13070.1454 | 52W Range 0.11042.46 | 5 Year PE Ratio Range -5.80-1.50 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.71% | ||
| 1 Month | -43.27% | ||
| 3 Months | -59.48% | ||
| 6 Months | -62.85% | ||
| 1 Year | -90.52% | ||
| 3 Years | -96.24% | ||
| 5 Years | -93.38% | ||
| 10 Years | -95.37% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -21.93 | |||
ROE last 12 Months | -85.38 | |||
ROA (5Y Avg) | -26.38 | |||
ROA last 12 Months | -23.35 | |||
ROC (5Y Avg) | -30.16 | |||
ROC last 12 Months | -22.15 | |||
Return on invested Capital Q | -5.00 | |||
Return on invested Capital Y | -3.94 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 8.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.30 | ||||
| 1.87 | ||||
| 1.07 | ||||
| 62.10 | ||||
| -3.70 | ||||
| -0.02 | ||||
| 2.27 | ||||
| 0.05 | ||||
| 13.33M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.20 | ||||
| 0.40 | ||||
| 0.54 | ||||
| 3.57 | ||||
| -4.50 | ||||
| Leverage Ratio | 4.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.90 | ||||
| -37.40 | ||||
| -3.00 | ||||
| -96.60 | ||||
| -52.26 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.18M | ||||
| 0.10 | ||||
| -6.02 | ||||
| -8.05 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.06 | - |
| Q03 2022 | - | -0.02 | - |
| Q02 2022 | - | -0.02 | - |
| Q01 2022 | - | -0.02 | - |
| Q03 2021 | - | -0.02 | - |
| Q02 2021 | - | -0.02 | - |
| Q01 2021 | - | -0.02 | - |
| Q04 2020 | - | -0.03 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2012 QR | - | - | - |
| 6/2012 QR | - | - | - |
| 12/2012 FY | - | - | - |
| 12/2013 FY | - | - | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 514.53K |
| Shares Outstanding | 11.43K |
| Shares Float | 7.57M |
| Trades Count | 1.02K |
| Dollar Volume | 69.46K |
| Avg. Volume | 1.11M |
| Avg. Weekly Volume | 1.11M |
| Avg. Monthly Volume | 1.30M |
| Avg. Quarterly Volume | 916.86K |
China Pharma Holdings Inc. (AMEX: CPHI) stock closed at 0.139 per share at the end of the most recent trading day (a 2.58% change compared to the prior day closing price) with a volume of 514.53K shares and market capitalization of 1.59M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 246 people. China Pharma Holdings Inc. CEO is Zhilin Li.
The one-year performance of China Pharma Holdings Inc. stock is -90.52%, while year-to-date (YTD) performance is -85.51%. CPHI stock has a five-year performance of -93.38%. Its 52-week range is between 0.1104 and 2.459, which gives CPHI stock a 52-week price range ratio of 1.22%
China Pharma Holdings Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.87, a price-to-sale (PS) ratio of 1.07, a price to cashflow ratio of 62.10, a PEG ratio of -, a ROA of -23.35%, a ROC of -22.15% and a ROE of -85.38%. The company’s profit margin is -52.26%, its EBITDA margin is -3.00%, and its revenue ttm is $5.18 Million , which makes it $0.10 revenue per share.
Of the last four earnings reports from China Pharma Holdings Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. China Pharma Holdings Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for China Pharma Holdings Inc. is — (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for China Pharma Holdings Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
China Pharma Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
China Pharma Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.39, ATR14 : 0.03, CCI20 : -74.84, Chaikin Money Flow : -0.28, MACD : -0.03, Money Flow Index : 69.71, ROC : -10.90, RSI : 32.29, STOCH (14,3) : 15.50, STOCH RSI : 0.55, UO : 43.53, Williams %R : -84.50), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of China Pharma Holdings Inc. in the last 12-months were:
China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
CEO: Zhilin Li
Telephone: +86 89866811730
Address: Second Floor, No. 17, Jinpan Road, Haikou 570216, , CN
Number of employees: 246
